Editas Medicine Files 8-K on Financials
Ticker: EDIT · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1650664
Sentiment: neutral
Topics: financial-reporting, operations
TL;DR
Editas Medicine dropped an 8-K on Jan 13th covering financials and operations.
AI Summary
Editas Medicine, Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition. The filing also includes information related to Regulation FD disclosure and financial statements and exhibits. The company is incorporated in Delaware and headquartered in Cambridge, Massachusetts.
Why It Matters
This 8-K filing provides crucial updates on Editas Medicine's financial health and operational results, which are important for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This filing is a standard 8-K reporting routine financial and operational information, not indicating any immediate or significant new risks.
Key Players & Entities
- Editas Medicine, Inc. (company) — Registrant
- January 13, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- Cambridge, Massachusetts (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing by Editas Medicine, Inc.?
The primary purpose of this 8-K filing is to report on Editas Medicine, Inc.'s results of operations and financial condition, as well as to provide Regulation FD disclosures and financial statements and exhibits.
On what date was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 13, 2025.
In which state is Editas Medicine, Inc. incorporated?
Editas Medicine, Inc. is incorporated in Delaware.
What is the business address of Editas Medicine, Inc.?
The business address of Editas Medicine, Inc. is 11 Hurley Street, Cambridge, Massachusetts 02141.
What is the SIC code for Editas Medicine, Inc.?
The Standard Industrial Classification (SIC) code for Editas Medicine, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 754 words · 3 min read · ~3 pages · Grade level 12.2 · Accepted 2025-01-13 09:03:53
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share EDIT The Nasdaq Sto
- $270 million — s of December 31, 2024 of approximately $270 million (the "Financial Information"). The Fina
Filing Documents
- edit-20250113.htm (8-K) — 28KB
- editasmedicinehighlightsin.htm (EX-99.1) — 38KB
- image_0.jpg (GRAPHIC) — 10KB
- 0001650664-25-000003.txt ( ) — 210KB
- edit-20250113.xsd (EX-101.SCH) — 2KB
- edit-20250113_lab.xml (EX-101.LAB) — 21KB
- edit-20250113_pre.xml (EX-101.PRE) — 12KB
- edit-20250113_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On January 13, 2025, Editas Medicine, Inc. (the "Company") disclosed that it had preliminary unaudited cash, cash equivalents, and marketable securities as of December 31, 2024 of approximately $270 million (the "Financial Information"). The Financial Information contained in this Item 2.02 of this Current Report on Form 8-K is unaudited and preliminary, subject to the completion of the Company's fourth quarter and fiscal year financial closing procedures, and does not present all information necessary for an understanding of the Company's financial condition as of December 31, 2024 or the results of operations for the three months or fiscal year ended December 31, 2024. The Financial Information may differ materially from the amounts that will be reflected in the Company's consolidated financial statements for the three months or full year ended December 31, 2024. The information contained in Item 2.02 in this Current Report on Form 8-K shall not be deemed "Filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 (the "Securities Act") or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On January 13, 2025, the Company issued a press release announcing new in vivo preclinical proof of concept data, anticipated 2025 key milestones, and three-year strategic priorities, a copy of which press release is attached hereto as Exhibit 99.1. The information in this Item 7.01 and Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued by the Company on January 13, 2025* 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * This exhibit shall be deemed to be furnished and not filed.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EDITAS MEDICINE, INC. Date: January 13, 2025 By: /s/ Erick Lucera Erick Lucera Chief Financial Officer